VIGH receives NIH grants to reduce risk of kidney disease and epilepsy 

Researchers in the Vanderbilt Institute for Global Health (VIGH) have received two new grants from the National Institutes of Health (NIH) aimed at reducing the risk of kidney disease in HIV-infected adults and improve the treatment of epilepsy in children in Nigeria.

The first grant will provide $3.1 million over five years to support a randomized controlled trial of 2,200 HIV-infected adults on combination antiretroviral therapy who are genetically susceptible to developing kidney-related complications. The principal investigators are C. William Wester, M.D., MPH, professor of Medicine in the Vanderbilt University School of Medicine, and Muktar Aliyu, M.D., Dr.P.H, VIGH associate director for Research, associate professor of Health Policy and Medicine at Vanderbilt and associate professor of Family and Community Medicine at Meharry Medical College.

The second award will provide $372,000 over two years to address a phenomenon known as the 'epilepsy treatment gap', in which up to 90 percent of children with epilepsy in low- and middle-income countries are not receiving consistent and appropriate treatment. Vanderbilt researchers led by principal investigator Edwin Trevathan, M.D., MPH, professor of Pediatrics and Neurology, and Aliyu, the grant's co-principal investigator. Click here for more information. 

Puerto Rico hurricane relief effort

Global Health Funding Opportunities